IL11 and neoplasm: Because IL-11 plays a mediating role in cancer-related bone metastasis, researchers developed a ligand-targeted peptidomimetic drug, namely BMTP-11 (bone metastasis-targeting peptidomimetic-11), which binds to IL-11Rα in the tumor vascular endothelium of castrate-resistant prostate cancer patients (158).